Breaking News Instant updates and real-time market news.

AMT

American Tower

$237.87

7.52 (3.26%)

, ARNA

Arena Pharmaceuticals

$51.22

-1.7 (-3.21%)

08:25
09/04/19
09/04
08:25
09/04/19
08:25

Wells Fargo to hold a conference

2019 Wells Fargo Healthcare Conference will be held in Boston on September 4-5 with webcasted company presentations to begin on September 4 at 8:30 am; not all company presentations may be webcasted. Webcast Link

AMT

American Tower

$237.87

7.52 (3.26%)

ARNA

Arena Pharmaceuticals

$51.22

-1.7 (-3.21%)

ADAP

Adaptimmune

$1.55

-0.06 (-3.73%)

AFMD

Affimed N.V.

$2.76

-0.01 (-0.36%)

TFX

Teleflex

$360.77

-2.92 (-0.80%)

EOLS

Evolus

$16.10

-1.07 (-6.23%)

TPTX

Turning Point Therapeutics

$51.20

-3.21 (-5.90%)

SNSS

Sunesis

$0.97

0.14 (16.87%)

SIEN

Sientra

$6.33

-0.5 (-7.32%)

HALO

Halozyme

$16.16

-0.37 (-2.24%)

GMED

Globus Medical

$49.60

-1.47 (-2.88%)

BDX

Becton Dickinson

$248.19

-5.56 (-2.19%)

GTS

Triple-S

$19.96

-0.62 (-3.01%)

IMMU

Immunomedics

$12.58

-0.21 (-1.64%)

TBPH

Theravance Biopharma

$21.47

-0.57 (-2.59%)

SEM

Select Medical

$16.03

-0.185 (-1.14%)

NUVA

NuVasive

$63.06

-0.43 (-0.68%)

MMSI

Merit Medical

$34.13

-0.65 (-1.87%)

INFI

Infinity Pharmaceuticals

$1.16

0.01 (0.87%)

EBS

Emergent BioSolutions

$50.21

6.37 (14.53%)

CALA

Calithera Biosciences

$3.92

-0.075 (-1.88%)

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 05

    Sep

  • 09

    Sep

  • 09

    Sep

  • 19

    Sep

  • 25

    Sep

  • 27

    Sep

  • 23

    Oct

  • 13

    Nov

  • 06

    Sep

AMT American Tower
$237.87

7.52 (3.26%)

08/19/19
KEYB
08/19/19
NO CHANGE
Target $253
KEYB
Overweight
American Tower price target raised to $253 from $225 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for American Tower (AMT) to $253 from $225 as he believes the tower operators are the key beneficiaries of 5G network deployments by U.S. carriers with the T-Mobile (TMUS)/Sprint (S) merger enabling upside organic growth drivers coming from Dish (DISH) and a potential acceleration from AT&T (T)/Verizon (VZ). He reiterates an Overweight rating on American Tower's shares.
08/01/19
JPMS
08/01/19
NO CHANGE
JPMS
JPMorgan upgrades Crown Castle to Overweight, downgrades SBA to Neutral
JPMorgan analyst Philip Cusick upgraded Crown Castle International (CCI) to Overweight from Neutral and raised his price target for the shares to $150 from $125. The analyst also downgraded SBA Communications (SBAC) to Neutral from Overweight while raising his price target for the shares to $270 from $220. He keeps a Neutral rating on American Tower (AMT) with an increased price target of $220. Despite's Crown's "massive" investment in fiber and small cells, the company's underlying domestic macro business is underappreciated relative to peers, Cusick tells investors in a research note. Crown Castle is trading at nearly a five-turn discount to SBA Communications, the widest spread in over a decade, says the analyst. He recommends investors maintain some exposure to towers, but believes that "valuations have become stretched."
07/15/19
KEYB
07/15/19
NO CHANGE
Target $225
KEYB
Overweight
American Tower price target raised to $225 from $207 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for American Tower to $225 from $207 saying he has not seen peak tower valuations. As the wireless industry's structure becomes more clear, the analyst believes ample growth opportunities exist and he does not see risk to Q2 or 2019 estimates. Nispel reiterates an Overweight rating on the shares.
08/01/19
RHCO
08/01/19
NO CHANGE
Target $230
RHCO
Buy
American Tower price target raised to $230 from $210 at SunTrust
SunTrust analyst Greg Miller raised his price target on American Tower to $230 and kept his Buy rating after its Q2 earnings beat and raised guidance. The analyst also points to the quarter's strong organic billings growth, cash flow generation, and expanding margins, stating that the runway for cash flow and dividend growth at American Tower will be long.
ARNA Arena Pharmaceuticals
$51.22

-1.7 (-3.21%)

01/29/19
CANT
01/29/19
INITIATION
Target $62
CANT
Overweight
Arena Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young assumed coverage of Arena Pharmaceuticals (ARNA) and kept an Overweight rating on the shares while dropping her firm's price target to $62 from $67. The analyst updated her model to reflect Arena's deal with United Therapeutics for ralinepag. Her base case peak sales are $2.5B for etrasimod, and she also gives some credit to Phase 2 olorinab in pain and ralenipag royalties. Bowel disease represents a large and growing market in immunology, and etrasimod is well positioned with strong efficacy and safety in ulcerative colitis compared to Celgene's (CELG) ozanimod, Young tells investors in a research note. Over time, the analyst sees potential for etrasimod expansion into indications beyond bowel disease due to its safety profile.
01/29/19
01/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dell Technologies (DELL) initiated with an Outperform at Raymond James. 2. MasterCard (MA) and Visa (V) were initiated with a Buy at Jefferies. 3. Eiger BioPharmaceuticals (EIGR) initiated with an Outperform at Baird. 4. Arena Pharmaceuticals (ARNA) assumed with an Overweight at Cantor Fitzgerald. 5. Southern Copper (SCCO) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/18
BREN
12/13/18
INITIATION
Target $55
BREN
Buy
Arena Pharmaceuticals initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Arena Pharmaceuticals with a Buy rating and $55 price target, citing his view that ralinepag still has upside potential and that etrasimod may "emerge a winner in the crowded IBD area." He also believes that olorinab, which is in Phase 2 development for visceral pain associated with IBD and IBS, may eventually be worth as much, or more, than ralinepag, Trucchio tells investors.
04/03/19
FBCO
04/03/19
NO CHANGE
Target $77
FBCO
Outperform
Arena Pharmaceuticals price target raised to $77 from $63 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Arena Pharmaceuticals to $77 from $63 as he believes etrasimod has an opportunity to emerge as the oral agent of choice in the treatment of moderate-to-severe IBD. While several effective biologic approaches exist to manage IBD, the analyst received feedback that a safe and effective oral agent will likely play a major long-term role in managing patients' refractory to SoC, TNF-alpha antagonists. Etrasimod may be the 3rd or 4th oral agent to the market, but Auster sees its clinical profile supporting it as the best agent. The analyst reiterates an Outperform rating on the shares.
ADAP Adaptimmune
$1.55

-0.06 (-3.73%)

07/29/19
07/29/19
NO CHANGE

Adaptimmune management to meet with Morgan Stanley
Meeting to be held in Boston, MA on July 29 hosted by Morgan Stanley.
08/02/19
08/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Oshkosh (OSK) downgraded to Sector Weight from Overweight at KeyBanc with analyst Steve Barger saying that while he thinks Oshkosh is a better story than some other machinery names given solid execution and the potential for some growth or at least stability from its non- Access segments, he sees more room for negative catalysts than positive due to the deceleration in macro data, a growing view that AWP will be flat-to-down next year, and order and backlog contraction against a tough comp from FY19. 2. Square (SQ) downgraded to Underperform from Outperform at Evercore ISI. 3. Adaptimmune (ADAP) downgraded to Neutral from Buy at Guggenheim with analyst Michael Schmidt saying he believes visibility into the opportunity for the company's pipeline remains limited, particularly following discontinuation of the MAGEA10 program, reports of 3 new patient deaths, and resignation of the company's CMO. 4. Hilton Grand Vacations (HGV) downgraded to Underweight from Neutral at JPMorgan with analyst Brandt Montour saying he expects poor sentiment to weigh on shares until the company's contract sales reaccelerate in a consistent way, which he feels is not likely until 2020. 5. Valaris (VAL) downgraded to Market Perform from Outperform at Wells Fargo with analyst Coleman Sullivan saying he reduced his EBITDA forecasts through 2021 to account for revised rig startup assumptions, more conservative utilization and dayrate assumptions on floaters and revised cost assumptions. Sullivan, who continues to be disappointed by the lack of contracts at rates peers are able to achieve, sees the company's outlook having more inherent risk going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/02/19
GUGG
08/02/19
DOWNGRADE
GUGG
Neutral
Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt downgraded Adaptimmune to Neutral from Buy as he believes visibility into the opportunity for the company's pipeline remains limited, particularly following discontinuation of the MAGEA10 program, reports of 3 new patient deaths, and resignation of the company's CMO. Additionally, financing needs may be an overhang, said Schmidt. While results to date for MAGE-A4 in synovial sarcoma "look intriguing," its commercial opportunity is small, added Schmidt.
08/01/19
GUGG
08/01/19
DOWNGRADE
GUGG
Neutral
Adaptimmune downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Adaptimmune to Neutral from Buy.
AFMD Affimed N.V.
$2.76

-0.01 (-0.36%)

03/28/19
LEER
03/28/19
INITIATION
Target $8
LEER
Outperform
Affimed N.V. initiated with an Outperform at SVB Leerink
SVB Leerink initiated Affimed with an Outperform and $8 price target.
09/11/18
WELS
09/11/18
NO CHANGE
WELS
Amgen's AMG420 risk overstated, says Wells Fargo
Wells Fargo analyst Jim Birchenough believes shares of Bluebird Bio (BLUE) have been under pressure on concerns regarding potential competitive risk to BCMA CAR T therapeutic bb2121 from Amgen's (AMGN) bispecific T cell engager AMG420. The analyst highlights that AMGN420 is a continuous IV infusion and in his opinion not a viable competitor to a single bb2121 cell therapy dose, particularly given long-term durability of response with bb2121. Further, he notes that Amgen's approved first generation CD19 bispecific engager, BLINCYTO, is dosed as a continuous IV for 4 weeks out of every 6 and achieved only $175M in sales in 2017 following 2015 approval. He does not view this dose schedule for first generation bispecific T cell engagers as commercially viable in a more chronic cancer. Additionally, the analyst points out that Affimed (AFMD) also has a preclinical BCMA engager AFM26, established proof-of-concept data for CD30 bispecific AFM13, and upcoming proof-of-concept data for CD19 bispecific AFM11.
10/09/18
BMOC
10/09/18
NO CHANGE
Target $5
BMOC
Outperform
Affimed N.V.'s clinical trial hold on AFM11 'likely temporary', says BMO Capital
BMO Capital analyst Do Kim kept his Outperform rating and $5 price target on Affirmed N.V., saying the clinical hold placed on its AFM11 phase 1 trial is likely to be "temporary" since the three "serious adverse events" cited were identified as neurotoxicities. While he lowers his probability of success in acute lymphoblastic leukemia to 25% from 30% and keeps his probability in non-Hodgkin lymphoma at a "low" 15%, Kim calls for investors to buy Affirmed shares on weakness since the clinical hold is not likely to become "program ending".
10/09/18
RHCO
10/09/18
NO CHANGE
Target $5
RHCO
Buy
Affimed N.V. price target lowered to $5 from $7 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on Affirmed to $5 after the FDA placed a clinical hold on its T cell engager AFM11 phase 1 trial. The analyst keeps his Buy rating on the shares however, saying he sees no read-through to the company's NK cell engager platform or any impact on the recent NK cell engager Genentech deal. Lawson adds that commentary from the management indicates that the "series adverse events" in the study hold are "likely drug-related and from a CD19-related neurotoxicity" and should not impact the ongoing development of AFM13.
TFX Teleflex
$360.77

-2.92 (-0.80%)

06/20/19
RAJA
06/20/19
NO CHANGE
RAJA
Teleflex voluntary recall manageable, says Raymond James
Raymond James analyst Lawrence Keusch maintained a Strong Buy rating and $350 price target on Teleflex after the company announced a "manageable" voluntary recall For one of its endotracheal tubes. Keusch noted that there is no revenue impact, and an immaterial $1M pretax profit & loss impact from the cost of recalling the product and discarding the inventory.
08/05/19
JMPS
08/05/19
NO CHANGE
Target $395
JMPS
Outperform
Teleflex price target raised to $395 from $325 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Teleflex to $395 and kept his Outperform rating after its Q2 earnings beat, saying the quarter was "particularly impressive" as organic growth accelerated from Q1 into a double-digit range. The analyst believes that the stock should continue to appreciate given the management's efforts to boost profitability through "restructuring initiatives and manufacturing excellence programs."
08/05/19
JMPS
08/05/19
NO CHANGE
Target $395
JMPS
Outperform
Teleflex price target raised to $395 from $325 at JMP Securities
JMP Securities analyst David Turkaly raised his price target on Teleflex to $395 and kept his Outperform rating after its Q2 earnings beat, saying the quarter was "particularly impressive" as organic growth accelerated from Q1 into a double-digit range. The analyst believes that the stock should continue to appreciate given the management's efforts to boost profitability through "restructuring initiatives and manufacturing excellence programs."
08/02/19
NEED
08/02/19
NO CHANGE
Target $403
NEED
Buy
Teleflex price target raised to $403 from $325 at Needham
Needham analyst Mike Matson raised his price target on Teleflex to $403 and kept his Buy rating, saying its Q2 earnings beat shows the company caught "lightning in a bottle" with its UroLift system. The analyst points to the 9.6% organic revenue growth in the quarter in spite of the tougher comps and sees the 80bps decline in operating margins driven by the "incremental selling expense investments". Matson contends that the core business of TeleFlex is durable, and its Manta, and Percuvance could be sources of potential upside heading into 2020.
EOLS Evolus
$16.10

-1.07 (-6.23%)

07/31/19
STFL
07/31/19
NO CHANGE
STFL
Buy
Physician survey bodes well for Evolus and Revance, says Stifel
Stifel analyst Annabel Samimy said her survey of 50+ physicians in late June lead her to now believe that new toxins could have penetrations that exceed her current market-share estimates. The survey bodes well for Evolus (EOLS) in the near-term and for both Evolus and Revance (RVNC) in the longer-term while also indicating that Allergan's (AGN) Botox franchise may be more vulnerable than previously thought, Samimy tells investors. She previously had Evolus' Jeuveau reaching a peak market share of 15% and Revance's DaxibotulinumtoxinA reaching 20% shares by 2027, but her new "base case" assumes that Jeuveau peaks at 20% share and Daxi peaks at 25%, noted Samimy, who took down her Botox market share forecast for 2027 to 50%. Samimy raised her price target on Evolus shares to $33 from $30 and keeps a $50 price target on Revance while maintaining Buy ratings on both stocks.
07/11/19
WELS
07/11/19
NO CHANGE
Target $16
WELS
Market Perform
Evolus investors should keep eye on progressing Korean case, says Wells Fargo
A press report from Korea Biomedical Review indicates that the Seoul Central District Court has begun to test whether Nabota, the botulinum toxin of Daewoong Pharmaceutical, forms spores in the natural environment as an attempt to help decide the litigation between South Korean toxin manufacturers, Medytox and Daewoong, Wells Fargo analyst David Maris tells investors in a research note. Medytox sued Daewoong in 2017 alleging that Daewoong stole its botulinum toxin strain to manufacture its own, and thereby licensed U.S. cosmetic rights out to Evolus (EOLS) with a stolen botulinum toxin strain, Maris adds, while noting the report also said the first ruling should come in Q4 of this year. After speaking with company, Maris says the development is not unexpected. He believes, however, that investors should be aware of the progress and status of the litigation. The analyst keeps a Market Perform rating on Evolus shares with a $16 price target.
07/11/19
WELS
07/11/19
NO CHANGE
WELS
Market right in seeing rebate news as risk to pharmaceuticals, says Wells Fargo
Most pharmaceuticals stocks are down today due to a number of factors, including reports that the Trump Administration is abandoning its plan to lower drug prices by eliminating or restricting pharmacy benefit manager rebating, Wells Fargo analyst David Maris tells investors in a research note. The analyst believes the market is correctly interpreting the move as a potential risk to drugmakers. The absence of a rebating fix "does not mean there will not be a plan to address drug prices, but perhaps a greater risk that the absence of a rebate fix will put additional pressure to come up with ways to actually lower prices in ways that could more greatly impact drug makers than the rebating fix would have," contends Maris. He points out that companies with large cash-pay components of their business, like Allergan (AGN), Establishment Labs (ESTA), Evolus (EOLS), GlaxoSmithKline (GSK), Perrigo (PRGO), Revance (RVNC) and Sientra (SIEN), do not seem to be under as much pressure today as some of their more generic or pharma-concentrated peers. Maris says his Outperform ratings on Allergan, Establishment and Sientra are in part due to their cash-pay concentration
08/13/19
JMPS
08/13/19
NO CHANGE
Target $30
JMPS
Outperform
Evolus price target lowered to $30 from $35 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target on Evolus to $30 after its Q2 earnings miss and to reflect the updated share count for the stock in his valuation model. The analyst is keeping his Outperform rating however, noting that the company's launch of JEUVEAU on May 15 has exceeded expectations on several metrics, including "physician practices joining the JET trial" and patient satisfaction. Ellis maintains his expectation for JEUVEAU to achieve the management's target of a #2 position in the U.S. aesthetic toxin market.
TPTX Turning Point Therapeutics
$51.20

-3.21 (-5.90%)

09/04/19
WELS
09/04/19
NO CHANGE
Target $62
WELS
Outperform
Turning Point Therapeutics price target raised to $62 from $53 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Turning Point Therapeutics to $62 from $53 following updated interim phase 1/2 TRIDENT-1 data for repotrectinib in ROS1+ NSCLC and TRK+ solid tumors. The analyst reiterates an Outperform rating on the shares.
07/24/19
07/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sharps Compliance (SMED) initiated with a Buy at Roth Capital. 2. MobileIron (MOBL) initiated with a Buy at Craig-Hallum. 3. Berry Global (BERY) resumed with an Outperform at Wells Fargo. 4. Turning Point Therapeutics (TPTX) initiated with a Buy at Guggenheim. 5. Universal Display (OLED) initiated with a Hold at Berenberg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
05/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Pinterest (PINS) initiated with an Outperform at Baird, a Buy at Citi, a Sector Perform at RBC Capital, a Hold at Deutsche Bank, a Neutral at Credit Suisse, UBS, BofA/Merrill, Goldman Sachs, and JPMorgan, and an Equal Weight at Barclays. 2. Zoom Video (ZM) initiated with an Overweight at JPMorgan and Piper Jaffray, a Buy at BofA/Merrill, a Market Perform at Wells Fargo and JMP Securities, a Sector Perform at RBC Capital, a Sector Weight at KeyBanc, an Equal Weight at Morgan Stanley, a Hold at Stifel, and a Neutral at Credit Suisse and Goldman Sachs. 3. Turning Point Therapeutics (TPTX) initiated with an Outperform at Wells Fargo and a Buy at Canaccord and Goldman Sachs. 4. Brigham Minerals (MNRL) initiated with an Overweight at Piper Jaffray and Barclays, an Outperform at Wells Fargo, RBC Capital, and Credit Suisse, and a Buy at Goldman Sachs and UBS. 5. Brainsway (BWAY) initiated with an Outperform at Raymond James and Oppenheimer, a Buy at Ladenburg, and Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/19
GUGG
07/24/19
INITIATION
Target $58
GUGG
Buy
Turning Point Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Michael Schmidt initiated coverage of Turning Point Therapeutics with a Buy rating and $58 price target, stating that the market for selective tyrosine kinase inhibitors, or TKIs, targeting rare driver mutations in oncology represents a large and growing opportunity. The company's lead product candidate, repotrectinib, has demonstrated early but potent activity in certain non-small cell lung cancer patients positive and may be a best-in-class inhibitor for some solid tumor patients, Schmidt said.
SNSS Sunesis
$0.97

0.14 (16.87%)

12/20/18
HCWC
12/20/18
INITIATION
Target $0.5
HCWC
Neutral
Sunesis initiated with a Neutral at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Sunesis Pharmaceuticals with a Neutral rating and 50c price target. The analyst prefers to wait for additional clarity on vecabrutinib's potential before recommending the shares.
SIEN Sientra
$6.33

-0.5 (-7.32%)

07/25/19
CHLM
07/25/19
NO CHANGE
Target $14
CHLM
Buy
Sientra price target lowered to $14 from $20 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak lowered his price target for Sientra ( SIEN) to $14 from $20 to reflect stock offering. The analyst notes that Sientra's primary competitor Allergan (AGN) is voluntarily recalling its Biocell textured breast implants, creating a $35M void in the U.S. market to fill. Nowak reiterates a Buy rating on Sientra's shares.
08/09/19
WELS
08/09/19
NO CHANGE
Target $10
WELS
Outperform
Sientra setup favorable into second half, says Wells Fargo
Wells Fargo analyst David Maris noted that Sientra topped his expectations in both its Breast Products and miraDry segments in Q2, which he called a "solid quarter." He thinks the setup for the second half is favorable and believes the stock should start to outperform given that the near-term financing overhang was removed by the company's recent financing. Maris keeps an Outperform rating and $10 price target on Sientra shares.
07/24/19
WELS
07/24/19
NO CHANGE
WELS
Allergan recall to benefit Establishment and Sientra, says Wells Fargo
Wells Fargo analyst David Maris says Allergan (AGN) recalling worldwide its textured implants after Canada, France, and Australia removed them from the market is not unexpected. The company's total sales in 2018 were approximately $15.8B, with breast implants approximately $263M and textured breast implants $26M, Maris tells investors in a research note. He views the recall as "clearly good" for Establishment Labs (ESTA) and Sientra (SIEN), "which have not been implicated." Maris thinks both companies will continue to gain market share due to the recall.
HALO Halozyme
$16.16

-0.37 (-2.24%)

02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
07/01/19
CANT
07/01/19
NO CHANGE
Target $27
CANT
Overweight
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.
11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
GMED Globus Medical
$49.60

-1.47 (-2.88%)

05/24/19
WELS
05/24/19
DOWNGRADE
Target $41
WELS
Market Perform
Wells Fargo downgrade Globus Medical on increased spinal robotics competition
Wells Fargo analyst Lawrence Biegelsen downgraded Globus Medical (GMED) to Market Perform from Outperform and lowered his price target for the shares to $41 from $50. The analyst sees increased competitive dynamics in the U.S. spinal robotics market. He anticipates longer capital sales cycles as customers evaluate four competitive spinal robotic offerings in the market over the next few quarters. They include Zimmer Biomet's (ZBH) ROSA One platform, NuVasive's (NUVA) Pulse Surgical Intelligence system, Medtronic's (MDT) MazorX Stealth robotic system and Globus Medical's ExcelsiusGPS robotic navigation platform, Biegelsen tells investors in a research note. The analyst continues to believe Globus will drive above market growth in spine, but he sees more limited opportunity for multiple expansion in the near term.
07/09/19
CANT
07/09/19
NO CHANGE
Target $55
CANT
Overweight
Globus Medical shares attractive at current levels, says Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou believes shares of Globus Medical (GMED) are attractive at current levels. He reiterates an Overweight rating on the name with a $55 price target. The analyst expects Globus to "bounce back" in Q2. Further, there are multiple Excelsius enhancements expected in the second half of 2019 that should give the company a competitive advantage, Bijou tells investors in research note. He also believes the momentum of the company's underlying core spine business should continue in the second half of the year. The analyst sees limited downside risk in the shares as he believes the worst case Medtronic (MDT) competitive fears are likely reflected in Globus Medical's current price.
02/28/19
02/28/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Fitbit (FIT) upgraded to Buy from Neutral at DA Davidson analyst Tom Forte citing Q4 results and outlook for Q1 and FY19. 2. Hain Celestial (HAIN) upgraded to Overweight from Neutral at JPMorgan with analyst Ken Goldman citing the company's "compelling" investor day, the analyst has increased confidence in Hain's ability to drive margin growth over the next few years. 3. Athene Holding (ATH) upgraded to Outperform from Market Perform at BMO Capital with analyst James Fotheringham saying the valuation multiple on the stock may have finally passed its trough at its current 5.5-times two-year forward earnings multiple and believes that its core business should be valued at 6.4-times. 4. Wabco (WBC) upgraded to Neutral from Underweight at JPMorgan and to Hold from Sell at Vertical Research. 5. Globus Medical (GMED) upgraded to Buy from Neutral at UBS with analyst Matthew Taylor saying the company has delivered several quarters in a row of improving spine growth, which confirms robot placements are leading to implant pull-through. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/19
WELS
05/24/19
DOWNGRADE
Target $41
WELS
Market Perform
Globus Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen downgraded Globus Medical to Market Perform from Outperform and lowered his price target for the shares to $41 from $50.
BDX Becton Dickinson
$248.19

-5.56 (-2.19%)

08/06/19
PIPR
08/06/19
NO CHANGE
PIPR
Becton Dickinson price target lowered to $266 from $267 at Piper Jaffray
Piper Jaffray analyst William Quirk maintained an Overweight rating on Becton Dickinson, but lowered his price target on shares to $266 from $267, following the company's Q3 earnings results. Quirk said the quarter, which beat on EPS and missed slightly on revenue, with management reiterating FY19 guidance, was "good, not great." The analyst also noted that Becton Dickinson is accelerating the growth curve in the second half of the year, which he called a "positive indicator."
06/21/19
ARGS
06/21/19
NO CHANGE
Target $290
ARGS
Buy
FDA advisory committee review of Becton Dickinson's DCB's a positive, says Argus
Argus analyst David Toung kept his Buy rating and $290 price target on Becton Dickinson, saying the recommendation by the FDA advisory committee that the company performs additional evaluation of the long-term safety of its drug-coated balloons, or DCBs, is a "positive" for the stock. The analyst states that the committee "notably" highlighted the benefit of the balloons and did not recommend that the product is removed from the market. Toung adds that as Becton Dickinson progresses with its acquisition of C.R. Bard, it is "delivering" on revenue growth, margin expansion, and revenue synergies, even though the regulatory advisory from the FDA has lowered his assumed FY19 and FY20 EPS view by 45c and 25c to $11.75 and $13.15 respectively.
05/13/19
05/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
WELS
05/13/19
NO CHANGE
Target $265
WELS
Outperform
Becton Dickinson price target lowered to $265 from $280 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Becton Dickinson to $265 from $280 after the company reported mixed Q2 results and maintained 2019 underlying sales growth guidance while lowering the EPS outlook. The analyst reiterates an Outperform rating on the shares.
GTS Triple-S
$19.96

-0.62 (-3.01%)

IMMU Immunomedics
$12.58

-0.21 (-1.64%)

08/19/19
CANT
08/19/19
INITIATION
Target $28
CANT
Overweight
Immunomedics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Varun Kumar initiated Immunomedics with an Overweight rating and $28 price target.
08/20/19
08/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Immunomedics (IMMU) initiated with an Overweight at Cantor Fitzgerald. 2. PayPal (PYPL) initiated with a Buy at Rosenblatt while Square (SQ) was initiated with a Neutral. 3. Sunrun (RUN), Vivint Solar (VSLR), and Sunnova Energy (NOVA) initiated with an Overweight at KeyBanc. 4. Spotify (SPOT) initiated with an Equal Weight at Consumer Edge. 5. Silk Road Medical (SILK) initiated with a Buy at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/09/19
PIPR
05/09/19
NO CHANGE
Target $20
PIPR
Overweight
Immunomedics refiling timeline should bring some relief, says Piper Jaffray
Immunomedics indicated that it is now in broad alignment with the FDA around the issues raised in the Complete Response Letter and is projecting a biologics license application resubmission for sacituzumab to occur in early Q4, Piper Jaffray analyst Joseph Catanzaro tells investors in a post-earnings research note. The analyst believes this timeline is largely in-line with consensus and should provide a "bit of relief." Investors may still have some questions around the Ascent trial timing, but given the FDA's apparent comfort with the clinical data, a further approval delay is unlikely given the extreme unmet need in triple-negative breast cancer, adds the analyst. He maintains an Overweight rating on Immunomedics with a $20 price target.
08/20/19
CANT
08/20/19
INITIATION
Target $28
CANT
Overweight
Cantor Fitzgerald starts Immunomedics at Overweight, sees approval forthcoming
As previously reported, Cantor Fitzgerald analyst Varun Kumar initiated Immunomedics with an Overweight rating and $28 price target. The current stock price reflects risks around FDA approval in triple-negative breast cancer due to the company receiving a complete response letter earlier this year, though he predicts sacituzumab govitecan will get regulatory approval since he views the issues raised in the CRL as not related to pre/clinical data. He also thinks, based on checks with key opinion leading doctors, that sacituzumab should have strong commercial uptake.
TBPH Theravance Biopharma
$21.47

-0.57 (-2.59%)

06/19/19
PIPR
06/19/19
NO CHANGE
Target $55
PIPR
Overweight
Piper reiterates $55 price target on Theravance after 'positive' data
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating on Theravance Biopharma with a $55 price target following the disclosure of "positive" 20-week results from the completed Phase II study which evaluated ampreloxetine in neurogenic orthostatic hypotension patients. The update provides "clear evidence" for ampreloxetine's durable efficacy and "clean" tolerability profile as patients continued to demonstrate clinically-relevant symptom improvements from baseline out to week 20, Van Buren tells investors in a research note. He believes ampreloxetine is a potential $500M-plus wholly-owned drug.
07/31/19
PIPR
07/31/19
NO CHANGE
Target $55
PIPR
Overweight
Theravance pipeline receiving 'very little credit,' says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren reiterates an Overweight rating on Theravance Biopharma with a $55 price target following the company's Q2 results. Trelegy's growth quarter-over-quarter in chronic obstructive pulmonary disease "continues to be impressive," Van Buren tells investors in a research note. The analyst adds that he's looking forward to the addition of asthma "further inflecting the launch" in 2020. Further, Yupelri's initial prescription trends are promising, contends Van Buren. He believes Theravance's pipeline is receiving "very little credit" and that there is "significant additional potential upside yet to be realized" in the shares.
08/16/19
CANT
08/16/19
NO CHANGE
CANT
Rinvoq read through 'very positive' for Theravance, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen said the FDA approval of AbbVie's (ABBV) Rinvoq with a black box warning was "very positive" for Theravance Biopharma (TBPH), as Theravance's TD-1473 is "likely the only JAK in development that may not receive a black box warning." Chen maintained an Overweight rating and $55 price target on Theravance Biopharma.
06/07/19
PIPR
06/07/19
NO CHANGE
Target $55
PIPR
Theravance recent selloff brings buying opportunity, says Piper Jaffray
After hosting a dinner with CEO Rick Winningham, Piper Jaffray analyst Tyler Van Buren recommends using the recent pullback in shares of Theravance Biopharma as a buying opportunity. The stock has experienced an aggressive pullback on concerns that are largely non-fundamental, Van Buren tells investors in a research note. Trelegy's addressable market has effectively doubled due to the recent positive asthma Captain data, says the analyst, who has a "high level of confidence" that the litigation will be resolved favorably soon. Further, he believes that at current price levels, Theravance shares are getting little credit for the ongoing Yupelri launch. Van Buren keeps an Overweight rating on the stock with a $55 price target.
SEM Select Medical
$16.03

-0.185 (-1.14%)

05/17/19
JMPS
05/17/19
UPGRADE
Target $18
JMPS
Outperform
Select Medical upgraded to Outperform with $18 price target at JMP Securities
As previously reported, JMP Securities analyst Peter Martin upgraded Select Medical to Outperform from Market Perform following his review of the company's 10Q for the first quarter. He notes the percentage of EBITDA contribution from the Critical Illness division is declining, but the unit is operationally stable. He also contends that the Concentra division, which has seen its average adjusted EBITDA margins expand 200bps over the last 24 months, "could be a cash cow if fueled properly." Martin added that he has become more comfortable with Select's ability to generate the free cash flow needed to meet its Concentra put option obligations in each of the next three years. He set a $18 price target on Select Medical shares.
05/17/19
JMPS
05/17/19
UPGRADE
JMPS
Outperform
Select Medical upgraded to Outperform from Market Perform at JMP Securities
12/14/18
LEHM
12/14/18
INITIATION
Target $20
LEHM
Equal Weight
Select Medical initiated with an Equal Weight at Barclays
Barclays analyst Patrick Feeley started Select Medical Holdings with an Equal Weight rating and $20 price target. The fast-growing IRF segment is just 15% of the company's revenue, and the majority of its business segments are low single-digit growers, says the analyst.
10/16/18
FBCO
10/16/18
INITIATION
Target $18
FBCO
Neutral
Select Medical initiated with a Neutral at Credit Suisse
Credit Suisse analyst A.J. Rice started Select Medical with a Neutral rating and $18 price target. While the analyst views most of its businesses as normalized 3% top-line growers, he believes the company has an opportunity to push growth higher over the next several years through development of inpatient rehab facilities.
NUVA NuVasive
$63.06

-0.43 (-0.68%)

07/29/19
BARD
07/29/19
DOWNGRADE
BARD
Neutral
NuVasive downgraded to Neutral at Baird
As reported previously, Baird analyst Jeff Johnson downgraded NuVasive to Neutral from Outperform. The analyst said his downgraded focused on the next 6-18 months when he believes the company spending and competitive pressures could both rise. under both scenarios, he sees limited upside to his estimates and believes the risk/reward looks balanced at current levels. Johnson maintained his $66 price target on NuVasive shares.
08/09/19
BMOC
08/09/19
NO CHANGE
Target $68
BMOC
Market Perform
NuVasive price target raised to $68 from $54 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on NuVasive to $68 but kept her Market Perform rating after its Analyst Day. The analyst says the presentation highlighted the company's innovation roadmap and financial commitments to increase revenue to $1.6B by 2024 but offered "nothing transformational".
07/29/19
BARD
07/29/19
DOWNGRADE
BARD
Neutral
NuVasive downgraded to Neutral from Outperform at Baird
MMSI Merit Medical
$34.13

-0.65 (-1.87%)

07/26/19
NEED
07/26/19
DOWNGRADE
NEED
Hold
Merit Medical downgraded to Hold from Buy at Needham
07/26/19
WELS
07/26/19
DOWNGRADE
Target $46
WELS
Market Perform
Merit Medical downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen downgraded Merit Medical Systems to Market Perform from Outperform and lowered his price target for the shares to $46 from $71.
07/26/19
WELS
07/26/19
DOWNGRADE
Target $46
WELS
Market Perform
Wells Fargo downgrades Merit Medical on lack of earnings visibility
Wells Fargo analyst Lawrence Biegelsen downgraded Merit Medical Systems to Market Perform from Outperform and lowered his price target for the shares to $46 from $71. Given the "soft" Q2, product mix dynamics, and some incremental headwinds from currency, China tariffs and Brightwater dilution, Merit Medical materially lowered its full-year gross margin and non-GAAP earnings outlook, Biegelsen tells investors in a research note. The analyst cite a lack of visibility and clarity around the earnings guidance reduction for his downgrade.
08/15/19
PIPR
08/15/19
NO CHANGE
PIPR
Merit Medical remains a favorite mid cap idea at Piper Jaffray
After speaking with a breast surgical oncologist that performs nearly 1,000 procedures per year, Piper Jaffray analyst Matt O'Brien says Merit Medical Systems remains his favorite mid cap name. The analyst keeps an Overweight rating on the shares with a $58 price target. The doctor users Merti's Savi Scout product in nearly all of her cases and noted significant patient benefits including aesthetics and comfort, O'Brien tells investors in a research note. He believes Savi Scout's benefits are even more pronounced for physicians from an ease-of-use perspective, along with removing more diseased tissue than the traditional wires while preserving healthy tissue. O'Brien thinks the Scout product will contribute meaningfully to Merit Medical's growth and gross margin expansion going forward.
INFI Infinity Pharmaceuticals
$1.16

0.01 (0.87%)

02/26/19
JONE
02/26/19
INITIATION
Target $3.5
JONE
Buy
Infinity Pharmaceuticals initiated with a Buy at JonesTrading
JonesTrading initiated Infinity Pharmaceuticals with a Buy and $3.50 price target.
06/27/19
06/27/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Underperform at Credit Suisse while Ford (F) and General Motors (GM) initiated with an Outperform. 2. Take-Two (TTWO) initiated with a Buy at SunTrust. 3. Infinity Pharmaceuticals (INFI) initiated with an Outperform at Oppenheimer. 4. Nomad Foods (NOMD) initiated with a Buy at Goldman Sachs. 5. Schlumberger (SLB) initiated with a Buy at Gabelli. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/26/19
OPCO
06/26/19
INITIATION
Target $3
OPCO
Outperform
Infinity Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated Infinity Pharmaceuticals with an Outperform rating and $3 price target.
06/27/19
06/27/19
INITIATION
Target $3

Outperform
Oppenheimer bullish on Infinity Pharmaceuticals, initiates with an Outperform
As previously reported, Oppenheimer analyst Kevin DeGeeter initiated Infinity Pharmaceuticals with an Outperform rating and $3 price target. The analyst notes that emerging evidence regulation of myeloid derived suppressor cells is an attractive strategy for expanding use of immune oncology therapies by reducing immune-suppression in tumor microenvironment, while data from MARIO-1 study demonstrating IPI-549 downregulates MDSCs in checkpoint resistant patients. Further, DeGeeter sees expectation that the Phase I/Ib MARIO-275 study of IPI-549 in combination with nivolumab for checkpoint inhibitor naive urothelial cancer providing proof-of-concept for the strategy by the second half of 2020.
EBS Emergent BioSolutions
$50.21

6.37 (14.53%)

05/09/19
WELS
05/09/19
NO CHANGE
Target $61
WELS
Market Perform
Emergent BioSolutions price target lowered to $61 from $68 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target on Emergent BioSolutions to $61 and kept his Market Perform rating after its miss on Q1 revenue and earnings last week. The analyst also lowers his FY19 and FY20 EPS outlook by 7c and 41c to $3.01 and $3.27 respectively, reflecting the delays in its negotiations for a follow-on contact for its AMAC2000 Smallpox Vaccine and the management's expectations for its FY19 earnings to be "even more heavily back half weighted."
09/04/19
WELS
09/04/19
UPGRADE
Target $64
WELS
Outperform
Emergent BioSolutions upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Davis Maris upgraded Emergent BioSolutions to Outperform from Market Perform and raised his price target for the shares to $64 from $61.
09/04/19
WELS
09/04/19
UPGRADE
Target $64
WELS
Outperform
Wells Fargo upgrades Emergent BioSolutions after 'major' contact win
Wells Fargo analyst Davis Maris upgraded Emergent BioSolutions to Outperform from Market Perform and raised his price target for the shares to $64 from $61. Emergent yesterday announced a much anticipated follow-on U.S. government contract for ACAM2000, its smallpox vaccine, Maris tells investors in a research note. Investors were worried about this delayed contract and were expecting a 10-year contract worth approximately $450M, well below the $2B value, adds the analyst. He believes the "major" contract removes a "major overhang" on shares of Emergent BioSolutions.
06/03/19
WELS
06/03/19
NO CHANGE
Target $61
WELS
Market Perform
Size, timeline of Emergent new contract 'a clear positive,' says Wells Fargo
Wells Fargo analyst David Maris notes that Emergent BioSolutions announced that it was awarded a 10-year contract award by the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services valued at approximately $535M. The company stated that the U.S. government has never awarded a 10-year contract for Vaccinia Immune Globulin Intravenous, and the last VIGIV contract was a 1-year $26M contract that was signed in February 2018, he points out, adding the contract prior to that was a 3-year $92M contract. The analyst views the size and timeline of the newly announced VIGIV contract as a clear positive. Further, Maris continues to think the ACAM2000 follow on contracts is a "when" not an "if" and expects the shares to trade higher when this contract negotiation is completed. He reiterates a Market Perform rating and a $61 price target on the stock.
CALA Calithera Biosciences
$3.92

-0.075 (-1.88%)

05/30/19
SBSH
05/30/19
INITIATION
Target $10
SBSH
Buy
Calithera Biosciences assumed with a Buy at Citi
Citi analyst Mohit Bansal assumed coverage Calithera Biosciences with a Buy rating and $10 price target. Under a prior analyst, Citi had a Buy rating on the shares with a $7 price target. Positive data mid-year from the small metastatic renal cell carcinoma trial could have read-through to the Cabo trial, Bansal tells investors in a research note.

TODAY'S FREE FLY STORIES

BA

Boeing

$386.31

1.7 (0.44%)

16:17
09/18/19
09/18
16:17
09/18/19
16:17
Periodicals
FAA head says won't unground 737 MAX until he flies it himself, CNBC says »

Federal Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

TNDM

TNDM

16:17
09/18/19
09/18
16:17
09/18/19
16:17
Hot Stocks
Tandem Diabetes says published results of t:slim X2 pump show reduced events »

Tandem Diabetes announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
09/18/19
09/18
16:17
09/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCP

HCP

$34.94

-0.18 (-0.51%)

16:16
09/18/19
09/18
16:16
09/18/19
16:16
Hot Stocks
HCP announces $1B commercial paper note program »

HCP announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEY

KeyCorp

$18.22

0.09 (0.50%)

16:16
09/18/19
09/18
16:16
09/18/19
16:16
Hot Stocks
KeyCorp lowers prime lending rate to 5.00% »

KeyCorp and its banking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

FBM

Foundation Building Materials

$18.92

0.03 (0.16%)

16:16
09/18/19
09/18
16:16
09/18/19
16:16
Syndicate
Foundation Building Materials files to sell 4.75M shares of common stock »

BofA Merrill Lynch and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
09/18/19
09/18
16:16
09/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAY

Dave & Buster's

$40.75

0.23 (0.57%)

16:15
09/18/19
09/18
16:15
09/18/19
16:15
Initiation
Dave & Buster's initiated  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRVB

Provention Bio

$9.67

0.3 (3.20%)

16:14
09/18/19
09/18
16:14
09/18/19
16:14
Syndicate
Provention Bio files to sell common stock, no amount given »

SVB Leerink and Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

COST

Costco

$292.37

0.86 (0.30%)

16:13
09/18/19
09/18
16:13
09/18/19
16:13
Downgrade
Costco rating change  »

Costco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

SPFI

South Plains Financial

$16.53

(0.00%)

16:12
09/18/19
09/18
16:12
09/18/19
16:12
Hot Stocks
South Plains Financial Chief Credit Officer Kevin Bass resigns »

South Plains Financial,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MLHR

Herman Miller

$44.54

0.04 (0.09%)

16:12
09/18/19
09/18
16:12
09/18/19
16:12
Hot Stocks
Herman Miller up 5% to $46.80 after Q1 results beat estimates »

The midpoint of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Oct

  • 22

    Oct

MLHR

Herman Miller

$44.50

(0.00%)

16:11
09/18/19
09/18
16:11
09/18/19
16:11
Hot Stocks
Herman Miller CFO: We continue to navigate the global tariff picture effectively »

Jeff Stutz, CFO, noted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Oct

  • 22

    Oct

ETSY

Etsy

$59.47

-0.45 (-0.75%)

16:10
09/18/19
09/18
16:10
09/18/19
16:10
Syndicate
Breaking Syndicate news story on Etsy »

Etsy announces $650M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

MLHR

Herman Miller

$44.50

(0.00%)

16:09
09/18/19
09/18
16:09
09/18/19
16:09
Hot Stocks
Herman Miller CEO says 'executing at a very high level' »

Andi Owen, President and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Oct

  • 22

    Oct

MSFT

Microsoft

$138.48

1.08 (0.79%)

16:08
09/18/19
09/18
16:08
09/18/19
16:08
Hot Stocks
Microsoft announces new $40B share repurchase program, 11% dividend hike »

Microsoft announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AVNW

Aviat Networks

$14.20

0.1 (0.71%)

16:08
09/18/19
09/18
16:08
09/18/19
16:08
Hot Stocks
Aviat Networks CEO Michael Pangia resigns, interim CEO Stan Gallagher appointed »

Aviat Networks appointed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$44.47

-0.03 (-0.07%)

16:07
09/18/19
09/18
16:07
09/18/19
16:07
Earnings
Herman Miller sees Q2 diluted EPS 85c-89c, consensus 85c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Oct

  • 22

    Oct

RH

RH

$171.11

-1.61 (-0.93%)

16:07
09/18/19
09/18
16:07
09/18/19
16:07
Earnings
RH raises FY19 guidance by 25c to $10.75-$11.01 after convertible debt offering »

Consensus $10.69. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DENN

Denny's

$22.61

0.08 (0.36%)

16:07
09/18/19
09/18
16:07
09/18/19
16:07
Initiation
Denny's initiated  »

Denny's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 13

    Nov

WING

Wingstop

$86.89

0.93 (1.08%)

16:06
09/18/19
09/18
16:06
09/18/19
16:06
Initiation
Wingstop initiated  »

Wingstop initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MLHR

Herman Miller

$44.47

-0.03 (-0.07%)

16:06
09/18/19
09/18
16:06
09/18/19
16:06
Earnings
Herman Miller reports Q1 adjusted EPS 84c, consensus 78c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Oct

  • 22

    Oct

ORN

Orion Group

$4.58

0.05 (1.10%)

16:06
09/18/19
09/18
16:06
09/18/19
16:06
Hot Stocks
Orion Group announces contract awards totaling about $29M »

Orion Group Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MSFT

Microsoft

$138.54

1.14 (0.83%)

16:05
09/18/19
09/18
16:05
09/18/19
16:05
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft announces new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

CBPO

China Biologic

$103.00

0.18 (0.18%)

16:04
09/18/19
09/18
16:04
09/18/19
16:04
Hot Stocks
China Biologic receives preliminary "going private" proposal for $120 per share »

China Biologic has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.